irinotecan + regorafenib

Irinotecan + regorafenib is an investigational combination therapy composed of two small molecule drugs, primarily studied for the treatment of metastatic colorectal cancer and other advanced gastrointestinal malignancies. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. Regorafenib is an oral multikinase inhibitor targeting several protein kinases involved in tumor angiogenesis (such as VEGFR1/2/3), oncogenesis (including KIT, RET, RAF), and the tumor microenvironment. The combination aims to leverage the cytotoxic effects of irinotecan with the antiangiogenic and antiproliferative properties of regorafenib to improve outcomes in patients who have progressed on standard therapies[1][2][4][8]. This regimen has been evaluated in multiple phase II and III clinical trials for metastatic colorectal cancer after failure of standard treatments[1][4][8].

Brand names

Stivarga (regorafenib)Camptosar (irinotecan hydrochloride)

Other names

REGIRIregorafenib plus irinotecanregorafenib and irinotecan combination